Solid Dividend Paid And Capex Coverage Ratio from 2010 to 2024
| SLDB Stock | USD 5.70 0.01 0.18% |
Dividend Paid And Capex Coverage Ratio | First Reported 2010-12-31 | Previous Quarter (62.17) | Current Value (65.27) | Quarterly Volatility 17.38618266 |
Check Solid Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Solid Biosciences' main balance sheet or income statement drivers, such as Interest Income of 7.4 M, Interest Expense of 24.7 M or Selling General Administrative of 20.8 M, as well as many indicators such as Price To Sales Ratio of 10.66, Dividend Yield of 0.0 or PTB Ratio of 1.01. Solid financial statements analysis is a perfect complement when working with Solid Biosciences Valuation or Volatility modules.
Solid | Dividend Paid And Capex Coverage Ratio |
Latest Solid Biosciences' Dividend Paid And Capex Coverage Ratio Growth Pattern
Below is the plot of the Dividend Paid And Capex Coverage Ratio of Solid Biosciences LLC over the last few years. It is Solid Biosciences' Dividend Paid And Capex Coverage Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Solid Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Dividend Paid And Capex Coverage Ratio | 10 Years Trend |
|
Dividend Paid And Capex Coverage Ratio |
| Timeline |
Solid Dividend Paid And Capex Coverage Ratio Regression Statistics
| Arithmetic Mean | (46.14) | |
| Coefficient Of Variation | (37.69) | |
| Mean Deviation | 13.72 | |
| Median | (51.33) | |
| Standard Deviation | 17.39 | |
| Sample Variance | 302.28 | |
| Range | 56.2426 | |
| R-Value | (0.04) | |
| Mean Square Error | 325.13 | |
| R-Squared | 0 | |
| Significance | 0.90 | |
| Slope | (0.14) | |
| Total Sum of Squares | 4,232 |
Solid Dividend Paid And Capex Coverage Ratio History
About Solid Biosciences Financial Statements
Solid Biosciences stakeholders use historical fundamental indicators, such as Solid Biosciences' Dividend Paid And Capex Coverage Ratio, to determine how well the company is positioned to perform in the future. Although Solid Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Solid Biosciences' assets and liabilities are reflected in the revenues and expenses on Solid Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Solid Biosciences LLC. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (62.17) | (65.27) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:Check out the analysis of Solid Biosciences Correlation against competitors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Quarterly Revenue Growth (1.00) | Return On Assets (0.35) | Return On Equity (0.66) |
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.